玻璃体内注射血管内皮生长因子抑制剂并发症的研究进展  

Advance in the study of complication of anti-vascular endothelial growth factor following intravitreal injection

作　　者：孟丽珠[1,2] 陈松[1,2] 

机构地区：[1]天津医科大学眼科临床学院,300020 [2]天津市眼科医院

出　　处：《眼科研究》2009年第11期1039-1043,共5页Chinese Ophthalmic Research

基　　金：天津市科技支撑重点项目资助(08ZCGYSF01700)

摘　　要：玻璃体内注射血管内皮生长因子(VEGF)抑制剂广泛用于年龄相关性黄斑变性(AMD)、中心性渗出性脉络膜视网膜病变及病理性近视引起的脉络膜新生血管(CNV)的治疗,也用于增生型糖尿病视网膜病变(PDR)、视网膜血管阻塞、早产儿视网膜病变及新生血管性青光眼等的治疗,已取得一定的疗效,但玻璃体内注射VEGF抑制剂也出现了很多并发症。就玻璃体内注射VEGF抑制剂对眼正常结构和生理功能的影响以及引起的眼压升高、视网膜色素上皮撕裂(RRPE)、视网膜脱离(RD)、眼内炎、注射相关损伤、全身不良反应等并发症进行综述。The efficacy of intravitrcal injection of anti vascular endothelial growth factor（VEGF） drug has been recognized for the treatment of choroidal neovascularization（CNV） secondary to age-related macular degeneration （AMD） , central exudative chorioretinopathy and pathological myopia, proliferative diabetic retinopathy （PDR）, retinal vein occlusion, retinopathy of prematurity and neovaseular glaucoma. The tendency of clinic application of anti-VEGF is increasing. Though the therapeutic effect of anti-VEGF has been confirmed,a variety of complications assoeiated with its usage were reported. This review summared the advancement of the complication in the clinical application of anti-VEGF therapy such as its effect on normal structure and physiological function of eye, intraocular pressure elevation, rips of retinal pigment epithelium （ RRPE ） , retinal detachment （ RD ） , endophthahnitis and systemic side-effects.

关 键 词：玻璃体 血管内皮生长因子抑制剂 并发症 脉络膜新生血管 

分 类 号：R770.5[医药卫生—眼科]